MARC record from Internet Archive

LEADER: 14035cam 2202341Ia 4500
001 ocn559734779
003 OCoLC
005 20200526044955.0
008 910211s1991 dcu ob 100 0 eng d
006 m o d
007 cr cn|||||||||
010 $a 91060585
040 $aMERUC$beng$epn$cMERUC$dCCO$dE7B$dOCLCQ$dUV0$dCASUM$dDKDLA$dOCLCE$dIDEBK$dCUS$dXFF$dOCLCQ$dORU$dOCLCQ$dN$T$dYDXCP$dCOF$dOCLCO$dFVL$dOCLCQ$dNLGGC$dOCLCO$dOCLCQ$dOCLCO$dOCLCQ$dAZK$dTOA$dCOCUF$dAGLDB$dMNU$dSUR$dMOR$dPIFBR$dOCLCQ$dOCLCA$dU3W$dOCLCA$dBUF$dOCLCO$dGILDS$dOCLCF$dOCLCO$dVNS$dOCLCO$dOCLCQ$dVTS$dLVT$dVT2$dSTF$dWRM$dNRAMU$dINT$dXFH$dEBLCP$dZCU$dICG$dOCLCQ$dN$T$dOCLCO$dAU@$dOCLCQ$dOCLCO$dOCLCA$dDKC$dOCLCO$dOCLCQ$dADU$dKIJ$dOCLCA
019 $a44954780$a228064206$a245535671$a475709283$a551505442$a629930493$a642456878$a647353775$a666933634$a722242379$a728013566$a814274466$a923259948$a961669896$a961673586$a962592044$a962635940$a972040095$a975242794$a975293706$a982314368$a984884368$a988438325$a990088987$a992114622$a994555841$a1003586155$a1016139292$a1017678387$a1018073288$a1021259647$a1058117548$a1112848367$a1118983063$a1119024608
020 $a058515547X$q(electronic bk.)
020 $a9780585155470$q(electronic bk.)
020 $z1280203560
020 $z9781280203565
020 $z9780309583367
020 $z0309583365
020 $z0309044901$q(pbk.)
020 $z9780309044905$q(pbk.)
035 $a(OCoLC)559734779$z(OCoLC)44954780$z(OCoLC)228064206$z(OCoLC)245535671$z(OCoLC)475709283$z(OCoLC)551505442$z(OCoLC)629930493$z(OCoLC)642456878$z(OCoLC)647353775$z(OCoLC)666933634$z(OCoLC)722242379$z(OCoLC)728013566$z(OCoLC)814274466$z(OCoLC)923259948$z(OCoLC)961669896$z(OCoLC)961673586$z(OCoLC)962592044$z(OCoLC)962635940$z(OCoLC)972040095$z(OCoLC)975242794$z(OCoLC)975293706$z(OCoLC)982314368$z(OCoLC)984884368$z(OCoLC)988438325$z(OCoLC)990088987$z(OCoLC)992114622$z(OCoLC)994555841$z(OCoLC)1003586155$z(OCoLC)1016139292$z(OCoLC)1017678387$z(OCoLC)1018073288$z(OCoLC)1021259647$z(OCoLC)1058117548$z(OCoLC)1112848367$z(OCoLC)1118983063$z(OCoLC)1119024608
042 $adlr
043 $an-us---
050 4 $aRC607.A26$bN53 1991eb
060 4 $aWD 308$bN617e 1991
072 7 $aMED$x022020$2bisacsh
072 7 $aHEA$x039020$2bisacsh
072 7 $aMJCJ2$2bicssc
082 04 $a362.1/969792/00973$220
100 1 $aNichols, Eve K.
245 10 $aExpanding access to investigational therapies for HIV infection and AIDS :$bMarch 12-13, 1990, conference summary /$cEve Nichols [writer] ; Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine.
260 $aWashington, D.C. :$bNational Academy Press,$c1991.
300 $a1 online resource (viii, 73 pages)
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
347 $adata file$2rda
504 $aIncludes bibliographical references.
588 0 $aPrint version record.
506 $3Use copy$fRestrictions unspecified$5MiAaHDL$2star
533 $aElectronic reproduction.$b[S.l.] :$cHathiTrust Digital Library,$d2010.$5MiAaHDL
538 $aMaster and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.$uhttp://purl.oclc.org/DLF/benchrepro0212$5MiAaHDL
583 1 $adigitized$c2010$hHathiTrust Digital Library$lcommitted to preserve$5MiAaHDL$2pda
505 0 $a""Expanding Access to Investigational Therapies for HIV Infection and AIDS""; ""Copyright""; ""PREFACE""; ""Contents""; ""EXPANDING ACCESS TO INVESTIGATIONAL THERAPIES FOR HIV INFECTION AND AIDS""; ""Expanding Access to Investigational Therapies March 12�13, 1990 Program""; ""1 HISTORICAL PERSPECTIVE""; ""EARLY DEVELOPMENT OF EXPANDED ACCESS""; ""Drug Amendments of 1962""; ""Access for Therapeutic Purposes""; ""Growing Confusion""; ""Modern Clinical Trials (Non-AIDS Drugs)""; ""THE ADVENT OF AIDS""; ""Broadening Participation""; ""Accelerating the Pace of Drug Development""
505 8 $a""Improving Response Capabilities""""Expedited Development""; ""Expanded Access""; ""Treatment Investigational New Drugs""; ""Parallel Track""; ""2 RIGHTS AND RESPONSIBILITIES""; ""FREEDOM OF CHOICE""; ""INFORMED CONSENT""; ""Information Resources""; ""Access""; ""Primary Care""; ""Difficult Choices""; ""COMPETING RIGHTS""; ""INSTITUTIONAL REVIEW BOARDS""; ""NEW ATTITUDES""; ""3 EVALUATION OF EXPANDED ACCESS PROGRAMS""; ""TREATMENT INVESTIGATIONAL NEW DRUGS""; ""POTENTIAL RISKS""; ""Examples from the Past""; ""The Target Population""; ""Safety Data""
505 8 $a""IMPACT ON CONVENTIONAL RANDOMIZED TRIALS""""THE PARALLEL TRACK EXPERIMENT""; ""4 CREATIVITY IN CLINICAL TRIALS""; ""THE CHANGING ENVIRONMENT""; ""CONVENTIONAL TRIALS""; ""PREFERENCE TRIALS""; ""LARGE, SIMPLE RANDOMIZED TRIALS""; ""Physician Participation""; ""Quality Control""; ""DATA FROM THE PARALLEL TRACK""; ""Efficacy Data""; ""Safety Data and Related Information""; ""Expectations""; ""5 DRUG INNOVATION AND THE PHARMACEUTICAL INDUSTRY""; ""TIME TO COMMERCIALIZATION""; ""DIRECT COSTS OF EXPANDED ACCESS""; ""Manpower Needs""; ""Drug Costs""; ""The Small Manufacturer""
505 8 $a""PRODUCT LIABILITY""""Concerns Specific to the Parallel Track""; ""Potential Solutions""; ""6 THIRD-PARTY PAYERS""; ""BLUE CROSS AND BLUE SHIELD""; ""HEALTH INSURANCE ASSOCIATION OF AMERICA""; ""HEALTH CARE FINANCING ADMINISTRATION""; ""Medicaid""; ""State Discretion""; ""Patient Care Costs""; ""Medicare""; ""RESOURCES FOR CLINICAL INVESTIGATION""; ""7 IMPROVING ACCESS TO CARE""; ""PEOPLE OF COLOR""; ""Resource Considerations""; ""Suspicion""; ""Informed Consent""; ""WOMEN""; ""The Gender Perspective""; ""Risk Factors""; ""Protocol Development""; ""Women as Vectors""; ""A New Approach""
505 8 $a""THE PEDIATRIC POPULATION""""Scientific Issues""; ""Social Issues""
546 $aEnglish.
650 0 $aAIDS (Disease)$xChemotherapy$xSocial aspects$zUnited States$vCongresses.
650 0 $aPharmacology, Experimental$xSocial aspects$zUnited States$vCongresses.
650 0 $aHIV infections$xChemotherapy$xSocial aspects$zUnited States$vCongresses.
650 7 $aMEDICAL$xAIDS & HIV.$2bisacsh
650 7 $aHEALTH & FITNESS$xDiseases$xAIDS & HIV.$2bisacsh
650 7 $aInfections à VIH.$2fmesh
650 7 $aSyndrome d'immunodéficience acquise.$2fmesh
650 7 $aPharmacology, Experimental$xSocial aspects.$2fast$0(OCoLC)fst01060281
651 7 $aUnited States.$2fast$0(OCoLC)fst01204155
650 2 $aEthics Committees, Research.
650 2 $aGovernment Regulation.
650 2 $aHealth Services Accessibility.
650 2 $aPersonal Autonomy.
650 2 $aPublic Policy.
650 2 $aRandom Allocation.
650 2 $aResearch Design.
650 2 $aSocial Control, Formal.
650 2 $aHIV Seropositivity.
650 2 $aAcquired Immunodeficiency Syndrome.
650 2 $aChild.
650 2 $aFederal Government.
650 2 $aHuman Experimentation.
650 2 $aInformation Dissemination.
650 2 $aPatient Selection.
650 2 $aResearch.
650 2 $aRisk.
650 2 $aSocioeconomic Factors.
650 2 $aGovernment.
650 2 $aHIV Infections.
650 2 $aInsurance, Health.
650 2 $aRisk Assessment.
650 2 $aEthics Committees.
650 2 $aFreedom.
650 2 $aInformation Services.
650 2 $aTherapeutic Human Experimentation.
650 2 $aWomen.
650 2 $aClinical Trials as Topic.
650 2 $aPatient Care.
650 2 $aVulnerable Populations.
650 2 $aInformed Consent.
650 2 $aResearch Subjects.
650 2 $aMinority Groups.
650 2 $aDrugs, Investigational.
650 2 $aDrug Industry.
650 2 $aFinancial Support.
650 2 $aHealth Care Economics and Organizations.
650 2 $aMethods.
650 2 $aEconomics.
650 2 $aHuman Rights.
650 2 $aSociology.
650 2 $aProbability.
650 2 $aIndustry.
650 2 $aPrinciple-Based Ethics.
650 2 $aSlow Virus Diseases.
650 2 $aEthics.
650 2 $aEpidemiologic Study Characteristics as Topic.
650 2 $aProfessional Staff Committees.
650 2 $aOrganizations.
650 2 $aEvaluation Studies as Topic.
650 2 $aPsychological Phenomena and Processes.
650 2 $aJurisprudence.
650 2 $aSocial Control Policies.
650 2 $aDelivery of Health Care.
650 2 $aPatient Rights.
650 2 $aScience.
650 2 $aPersons.
650 2 $aHealth Services.
650 2 $aEpidemiologic Research Design.
650 2 $aPharmaceutical Preparations.
650 2 $aPatient Care Management.
650 2 $aPopulation Characteristics.
650 2 $aCommunication.
650 2 $aAge Groups.
650 2 $aSexually Transmitted Diseases, Viral.
650 2 $aImmunologic Deficiency Syndromes.
650 2 $aRisk Management.
650 2 $aEpidemiologic Measurements.
650 2 $aLentivirus Infections.
650 2 $aSocial Sciences.
650 2 $aInformation Science.
650 2 $aBiomedical Research.
650 2 $aInsurance.
650 2 $aInvestigative Techniques.
650 2 $aTherapeutics.
650 2 $aHealth Care Quality, Access, and Evaluation.
650 2 $aQuality Assurance, Health Care.
650 2 $aTechnology, Industry, and Agriculture.
650 2 $aStatistics as Topic.
650 2 $aProfessional Practice.
650 2 $aPublic Health.
650 2 $aNatural Science Disciplines.
650 2 $aHealth Care Evaluation Mechanisms.
650 2 $aNamed Groups.
650 2 $aFinancing, Organized.
650 2 $aHumanities.
650 2 $aSexually Transmitted Diseases.
650 2 $aChemicals and Drugs.
650 2 $aEpidemiologic Methods.
650 2 $aVirus Diseases.
650 2 $aPolicy.
650 2 $aPsychiatry and Psychology.
655 4 $aElectronic books.
655 7 $aConference papers and proceedings.$2fast$0(OCoLC)fst01423772
655 2 $aCongress.
710 2 $aRoundtable for the Development of Drugs and Vaccines against AIDS (Institute of Medicine)
776 08 $iPrint version:$aNichols, Eve K.$tExpanding access to investigational therapies for HIV infection and AIDS.$dWashington, D.C. : National Academy Press, 1991$z0309044901$w(DLC) 91060585$w(OCoLC)23661748
856 40 $3Ebook Library$uhttp://public.eblib.com/choice/publicfullrecord.aspx?p=3375988
856 40 $3ebrary$uhttp://site.ebrary.com/id/10054979
856 40 $3EBSCOhost$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=14262
856 40 $3Google$uhttp://books.google.com/books?id=JfNrAAAAMAAJ
856 40 $3HathiTrust Digital Library, Limited view (search only)$uhttp://catalog.hathitrust.org/api/volumes/oclc/23661748.html
856 40 $3MyiLibrary$uhttp://www.myilibrary.com?id=20356
856 40 $3National Academies Press$uhttp://www.nap.edu/catalog.php?record_id=1778
856 40 $3National Academies Press$uhttp://books.nap.edu/catalog.php?record_id=1778
856 40 $3National Academies Press$uhttp://www.nap.edu/catalog/1778.html
856 40 $3National Academies Press$uhttp://www.nap.edu/1778
856 40 $3National Academies Press$uhttp://www.nap.edu/openbook.php?record_id=1778
856 40 $3ProQuest Ebook Central$uhttp://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=3375988
856 40 $uhttp://www.ncbi.nlm.nih.gov/books/NBK234125
856 40 $uhttps://www.ncbi.nlm.nih.gov/books/NBK234125
856 41 $3MyiLibrary, Table of contents$uhttp://www.myilibrary.com?id=20356&ref=toc
856 4 $3EBSCOhost$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=14262
856 40 $uhttps://ebookcentral.proquest.com/lib/columbia/detail.action?docID=3375988$zEbook Central Academic Complete
856 40 $uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=14262$xWMS$yEBSCO Academic Comprehensive Collection$xProvider: EBSCO$xsubscribed$xeLoaderURL$xuc4$xucocn559734779
856 $uhttp://books.nap.edu/catalog/1778.html
856 40 $3University of Alberta Access$uhttps://ebookcentral.proquest.com/lib/ualberta/detail.action?docID=3375988$z(Unlimited Concurrent Users)$zfrom Ebook Central Academic Complete
856 40 $3Concordia University of Edmonton Access$uhttp://ebookcentral.proquest.com/lib/concordiaab-ebooks/detail.action?docID=3375988$z(Unlimited Concurrent Users)$zfrom Ebook Central Academic Complete
856 40 $3Grande Prairie Regional College Access$uhttp://ebookcentral.proquest.com/lib/gprc-ebooks/detail.action?docID=3375988$z(Unlimited Concurrent Users)$zfrom Ebook Central Academic Complete
856 40 $3MacEwan University Access$uhttp://ebookcentral.proquest.com/lib/macewan-ebooks/detail.action?docID=3375988$z(Unlimited Concurrent Users)$zfrom Ebook Central Academic Complete
856 40 $3Red Deer College Access$uhttp://ebookcentral.proquest.com/lib/rdc/detail.action?docID=3375988$z(Unlimited Concurrent Users)$zfrom Ebook Central Academic Complete
856 40 $3Alberta Government Library Access$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=14262$z(Unlimited Concurrent Users)$zfrom EBSCO Academic Collection
938 $aEBL - Ebook Library$bEBLB$nEBL3375988
938 $aebrary$bEBRY$nebr10054979
938 $aEBSCOhost$bEBSC$n14262
938 $aProQuest MyiLibrary Digital eBook Collection$bIDEB$n20356
938 $aYBP Library Services$bYANK$n2309844
938 $aYBP Library Services$bYANK$n6012552
029 1 $aAU@$b000050961285
029 1 $aAU@$b000051481802
029 1 $aDEBBG$bBV043067348
029 1 $aDEBBG$bBV044106699
029 1 $aDEBSZ$b422565784
029 1 $aGBVCP$b80307994X
029 1 $aNZ1$b11927890
029 1 $aNZ1$b16094530
994 $aZ0$bP4A
948 $hHELD BY P4A - 1625 OTHER HOLDINGS